Clinical

NCCN guideline updates for CSCC emphasize immunotherapy as a cornerstone across disease stages, expanding its role from advanced disease into neoadjuvant and adjuvant settings.

Immunotherapy-related skin adverse events may correlate with improved tumor response and survival, underlining their clinical significance.

This year's meeting in Denver, Colorado, features more than 275 sessions, including 40 new offerings, and a fireside chat with EGOT winner John Legend.

The authors assess use of the novel assistant physician (AP) pathway and examine Missouri regulatory changes. They find limited supply impacts of APs and discuss implications.

Christopher Shade, PhD, shares insights for managed care leaders on oral peptide therapies.

Subcutaneous cancer therapy cuts chair time and IV needs, but brings site reactions, volume limits, and policy hurdles clinics must solve.

Subcutaneous amivantamab offers faster treatment, fewer infusion reactions, and improved convenience for patients with EGFR-mutated NSCLC, says Estelamari Rodriguez, MD, MPH.

Insulin affordability improved for Medicare Part D beneficiaries between 2019 and 2023, with more paying $35 or less for a 30-day supply.

This study assessed the impact of hyperpolypharmacy on hospital readmission risk in 2 Medicare populations and identified effects of postdischarge ambulatory care.

Patients with chronic or small lymphocytic leukemia now have a variety of treatment options, although a new report found not every patient was presented with multiple options.

The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, says Estelamari Rodriguez, MD, MPH.

UK real-world data show that bridging therapy before brexu-cel in mantle cell lymphoma boosts responses but also increases cytopenias and early mortality.

Maria Hordinsky, MD, discusses exciting results in alopecia areata, including some discussed at the Winter Clinical Dermatology Conference.

DLBCL is the most common subtype of non-Hodgkin lymphoma, known for its aggressiveness and heterogeneity. This presents treatment challenges if patients relapse following the initial chemoimmunotherapy regimen.

Explore frequently asked questions on IPF therapies, including approved drugs, emerging treatments, and approaches to slow fibrosis.

Higher social vulnerability was associated with lower dietary fiber intake and a hostile gut microbiome in patients with melanoma or sarcoma receiving immune checkpoint blockade.

GLP-1s and SGLT2s were associated with improved kidney outcomes and no increased safety risks in patients with T1D and CKD.

Male patients and those from minoritized racial and ethnic groups face longer times to treatment, especially in urban areas.

A phase 3 clinical trial found that the ustekinumab biosimilar CT-P43 demonstrated equivalent efficacy, safety, and immunogenicity to reference ustekinumab in patients with moderate to severe plaque psoriasis.

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Fred D. Lublin, MD, discusses therapy sequencing, deescalation, health equity, and the future of multiple sclerosis (MS) care delivery.

Racial gaps in curative treatment for early-stage NSCLC persist among Medicare beneficiaries, with Black patients less likely to receive surgery.

Subcutaneous cancer therapy trims chair time and costs, but volume limits and reactions matter—learn how clinics streamline workflows.

Experts decode NSCLC PD‑L1 trials, when immunotherapy alone works, why crossover matters, and who still benefits from adding chemotherapy.